menu
    • menu

    Find Vitamin D3 manufacturers, exporters & distributors on PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    dksh-m-2025-05-26

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    48

    API Suppliers

    API Suppliers

    19

    USDMF

    US DMFs Filed

    15

    CEP/COS

    CEP/COS Certifications

    2

    JDMF

    JDMFs Filed

    2

    EU WC

    EU WC

    0

    KDMF

    KDMF

    4

    NDC API

    NDC API

    0

    VMF

    NDC API

    22

    Listed Suppliers

    Other Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    3

    EDQM

    3

    USP

    1

    JP

    3

    Others

    FINISHED DOSAGE FORMULATIONS

    742

    FDF Dossiers

    FDF Dossiers

    6

    FDA Orange Book

    FDA (Orange Book)

    397

    Europe

    Europe

    37

    Canada

    Canada

    0

    Australia

    Australia

    6

    South Africa

    South Africa

    296

    Listed Dossiers

    Listed Dossiers

    8DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    358RELATED EXCIPIENT COMPANIES

    598EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 539

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    117

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    84

    API

    23

    FDF

    DIGITAL CONTENT

    2

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    25

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Vitamin d3, 67-97-0, Colecalciferol, Calciol, Oleovitamin d3, Ricketon
    Molecular Formula
    C27H44O
    Molecular Weight
    384.6  g/mol
    InChI Key
    QYSXJUFSXHHAJI-YRZJJWOYSA-N
    Vitamin D3
    Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.
    1 2D Structure

    Vitamin D3

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
    2.1.2 InChI
    InChI=1S/C27H44O/c1-19(2)8-6-9-21(4)25-15-16-26-22(10-7-17-27(25,26)5)12-13-23-18-24(28)14-11-20(23)3/h12-13,19,21,24-26,28H,3,6-11,14-18H2,1-2,4-5H3/b22-12+,23-13-/t21-,24+,25-,26+,27-/m1/s1
    2.1.3 InChI Key
    QYSXJUFSXHHAJI-YRZJJWOYSA-N
    2.1.4 Canonical SMILES
    CC(C)CCCC(C)C1CCC2C1(CCCC2=CC=C3CC(CCC3=C)O)C
    2.1.5 Isomeric SMILES
    C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. (3 Beta,5z,7e)-9,10-secocholesta-5,7,10(19)-trien-3-ol

    2. Calciol

    3. Cholecalciferols

    4. Vitamin D 3

    5. Vitamin D3

    2.2.2 Depositor-Supplied Synonyms

    1. Vitamin D3

    2. 67-97-0

    3. Colecalciferol

    4. Calciol

    5. Oleovitamin D3

    6. Ricketon

    7. Arachitol

    8. Trivitan

    9. Deparal

    10. Activated 7-dehydrocholesterol

    11. Delsterol

    12. Vigorsan

    13. Ebivit

    14. Vitamin D-3

    15. Colecalcipherol

    16. Quintox

    17. Colecalciferolum

    18. Cholecalciferolum

    19. (+)-vitamin D3

    20. D3-vicotrat

    21. D3-vigantol

    22. 1406-16-2

    23. Vi-de-3-hydrosol

    24. Neo Dohyfral D3

    25. Vitinc Dan-dee-3

    26. Cholecalciferol, D3

    27. Vigantol

    28. Vi-de3

    29. Duphafral D3 1000

    30. Feracol

    31. Delta-d

    32. Cc

    33. Chebi:28940

    34. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol

    35. Nsc 375571

    36. 9,10-secocholesta-5,7,10(19)-trien-3-beta-ol

    37. Provitina

    38. Micro-dee

    39. 7-dehydrocholesterol, Activated

    40. Vidde-3-hydrosol

    41. Vitamin D3 Solution

    42. Colecalciferol (inn)

    43. Colecalciferol [inn]

    44. Ncgc00159331-02

    45. Rampage

    46. Vitamin D3 10 Microg/ml In Acetonitrile

    47. (3beta,5z,7e)-9,10-secocholesta-5,7,10(19)-trien-3-ol

    48. (5z,7e)-(3s)-9,10-seco-5,7,10(19)-cholestatrien-3-ol

    49. (5z,7e)-(3s)-9,10-secocholesta-5,7,10(19)-trien-3-ol

    50. Dsstox_cid_6294

    51. Dsstox_rid_78090

    52. Dsstox_gsid_26294

    53. Vitamin D3 (cholecalciferol)

    54. 9,10-seco(5z,7e)-5,7,10(19)-cholestatrien-3beta-ol

    55. Colecalciferolo

    56. (3s,5z,7e)-9,10-secocholesta-5,7,10(19)-trien-3-ol

    57. Colecalciferolo [dcit]

    58. 9,10-secocholesta-5(z),7(e),10(19)-trien-3(.beta.)-ol

    59. Vigantol Oil

    60. (5e)-cholecalciferol

    61. Nsc-375571

    62. Colecalciferol D3

    63. (1s,3z)-3-[(2e)-2-[(1r,3as,7ar)-1-[(1r)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylene-cyclohexanol

    64. (s,z)-3-(2-((1r,3as,7ar,e)-7a-methyl-1-((r)-6-methylheptan-2-yl)octahydro-4h-inden-4-ylidene)ethylidene)-4-methylenecyclohexan-1-ol

    65. Colecalciferolum [inn-latin]

    66. Vitamin D 3

    67. 7-dehydrocholestrol, Activated

    68. Irradiated 7-dehydrocholesterol

    69. Ccris 5813

    70. Ccris 6286

    71. Hsdb 820

    72. Cholecalciferol Impurity A

    73. 7-dehydrocholesterol, Irradiated

    74. Vitamin D (cholecalciferol)

    75. Vitamin D3 Emulsifiable

    76. Einecs 200-673-2

    77. Einecs 215-797-2

    78. Mfcd00078131

    79. Unii-9vu1ki44gp

    80. Epa Pesticide Chemical Code 202901

    81. Vitamin D3 (as Cholecalciferol)

    82. Vitamin D3; Cholecalciferol

    83. 1c6v77qf41

    84. Devaron

    85. Videkhol

    86. Vitamin D Assay System Suitability

    87. 7-dehydrocholesterol Activated

    88. Unii-1c6v77qf41

    89. Nsc375571

    90. Granuvit D3

    91. Dp-r206

    92. Cas-67-97-0

    93. Prestwick_63

    94. Ak R215 Component Colecalciferol

    95. Ak-r215 Component Colecalciferol

    96. Cholecalciferol D3

    97. Cyclohexanol, 3-((2e)-2-((1r,3as,7ar)-1-((1r)-1,5-dimethylhexyl)octahydro-7a-methyl-4h-inden-4-ylidene)ethylidene)-4-methylene-, (1s,3z)-

    98. Cyclohexanol, 3-[(2e)-2-[(1r,3as,7ar)-1-[(1r)-1,5-dimethylhexyl]octahydro-7a-methyl-4h-inden-4-ylidene]ethylidene]-4-methylene-, (1s,3z)-

    99. 9,10-secocholesta-5,7,10-trien-3-ol

    100. Cholecalciferol [usp:ban:jan:iso]

    101. ()-vitamin D3

    102. 9,10-seco(5z,7e)-5,7,10(19)-cholestatrien-3-ol

    103. Delta-d (tn)

    104. 9,10-secocholesta-5,7,10(19)-trien-3-ol, (3beta,5z,7e)-

    105. Prestwick3_000429

    106. Bmse000507

    107. Upcmld-dp152

    108. Schembl3126

    109. 9vu1ki44gp

    110. Chembl1042

    111. Bspbio_000418

    112. Cholecalciferol; 67-97-0

    113. Cholecalciferol (jp17/usp)

    114. Bpbio1_000460

    115. Megxm0_000458

    116. Dtxsid6026294

    117. Upcmld-dp152:001

    118. Acon1_001997

    119. Hms2096e20

    120. Cholecalciferol, >=98% (hplc)

    121. 9,10-secocholestra-5,7,10(19)-trien-3-ol, (3beta,5z,7e)-

    122. Cholecalciferol, Analytical Standard

    123. Zinc4474460

    124. Tox21_111578

    125. Tox21_202546

    126. Bdbm50030475

    127. Lmst03020001

    128. S4063

    129. Cholecalciferol For System Suitability

    130. Akos015950641

    131. Ac-8884

    132. Ccg-268466

    133. Cs-1179

    134. Db00169

    135. Smp1_000068

    136. Vitamin D3 100 Microg/ml In Methanol

    137. Ncgc00091072-01

    138. Ncgc00159331-04

    139. Ncgc00260095-01

    140. Bs-42465

    141. Hy-15398

    142. Cholecalciferol (d3), Analytical Standard

    143. C05443

    144. D00188

    145. 9,10-secocholesta-5,7,10(19)-trien-3-ol

    146. Cholecalciferol, Meets Usp Testing Specifications

    147. 078v131

    148. 9,10-secocholesta-5,7,10(19)-trien-3?-ol

    149. Q139347

    150. (5e,7e)-9,10-secocholesta-5,7,10-trien-3-ol

    151. Q-201931

    152. 3-beta,z,7e-9,10-secocholestr-5,7,10(19)-trien-3-ol

    153. Vitamin D3 Solution, 100 Mug/ml In Ethanol, 97% (cp)

    154. (3beta,z,7e)-9,10-secocholesta-5,7,10(19)-trien-3-ol

    155. 9,10-secocholesta-5,7,10(19)-trien-3-ol, (3b,5z,7e)-

    156. Cholecalciferol, European Pharmacopoeia (ep) Reference Standard

    157. Colecalciferol, British Pharmacopoeia (bp) Reference Standard

    158. Cholecalciferol, United States Pharmacopeia (usp) Reference Standard

    159. Cholecalciferol For System Suitability, European Pharmacopoeia (ep) Reference Standard

    160. Vitamin D3 Solution, 1 Mg/ml In Ethanol, Ampule Of 1 Ml, Certified Reference Material

    161. (1s,3z)-3-[(2e)-2-[7a-methyl-1-(6-methylheptan-2-yl)-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol

    162. Cholecalciferol (vitamin D3), Pharmaceutical Secondary Standard; Certified Reference Material

    2.3 Create Date
    2004-09-16
    3 Chemical and Physical Properties
    Molecular Weight 384.6 g/mol
    Molecular Formula C27H44O
    XLogP37.9
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count1
    Rotatable Bond Count6
    Exact Mass384.339216023 g/mol
    Monoisotopic Mass384.339216023 g/mol
    Topological Polar Surface Area20.2 Ų
    Heavy Atom Count28
    Formal Charge0
    Complexity610
    Isotope Atom Count0
    Defined Atom Stereocenter Count5
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count2
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 2  
    Drug NameVitamin d
    PubMed HealthVitamin D
    Drug ClassesNutriceutical, Nutritive Agent, Vitamin Combination, Adult Formula
    Active IngredientErgocalciferol
    Dosage FormCapsule
    RouteOral
    Strength50,000 iu
    Market StatusPrescription
    CompanyBanner Pharmacaps

    2 of 2  
    Drug NameVitamin d
    PubMed HealthVitamin D
    Drug ClassesNutriceutical, Nutritive Agent, Vitamin Combination, Adult Formula
    Active IngredientErgocalciferol
    Dosage FormCapsule
    RouteOral
    Strength50,000 iu
    Market StatusPrescription
    CompanyBanner Pharmacaps

    4.2 Therapeutic Uses

    Bone Density Conservation Agents; Vitamins

    National Library of Medicine, SIS; ChemIDplus Record for Cholecalciferol (67-97-0), MESH Heading. Available from, as of March 15, 2006: https://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp

    MEDICATION (VET): Nutritional factor (Antirachitic)

    O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 1787

    Therapeutic doses of specific vitamin D analogs are used in the treatment of chronic hypocalcemia, hypophosphatemia, rickets, and osteodystrophy associated with various medical conditions including chronic renal failure, familial hypophosphatemia, and hypoparathyroidism (postsurgical or idiopathic, or pseudohypoparathyroidism). Some analogs have been found to reduct elevated parathyroid hormone concentrations in patients with renal osteodystrophy associated with hyperparathyroidism. Theoretically, any of the vitamin D analogs may be used for the above conditions, However, because of their pharmacologic properties, some may be more useful in certain situations than others. Alfacalcidol, calcitriol, and dihydrotachysterol are usually preferred in patients with renal failure since these patients have impaired ability to synthesize calcitriol from cholecalciferol and ergocalciferol; therefore, the response is more predictable. In addition, their shorter half-lives may make toxicity easier to manage (hypercalcemia reverses more quickly). Ergocalciferol may not be the preferred agent in the treatment of familial hypophosphatemia or hypoparathyroidism because the large doses needed are associated with a risk of overdose and hypercalcemia; dihydrotachysterol and calcitriol may be preferred. /Included in US product labeling/

    Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 2966

    4.3 Drug Warning

    Studies have shown that the elderly may have an increased need for vitamin D due to a possible decrease in the capacity of the skin to produce previtamin D3 or a decrease in exposure to the sun or impaired renal function or impaired vitamin D absorption.

    Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 2967

    Doses of vitamin D analogs that do not exceed the physiologic requirement are usually nontoxic. However, some infants and patients with sarcoidosis or hypoparathyroidism may have increased sensitivity to vitamin D analogs. /Vitamin D analogs/

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3541

    Acute or chronic administration of excessive doses of vitamin D analogs or enhanced responsiveness to physiologic amounts of ergocalciferol or cholecalciferol may lead to hypervitaminosis D manifested by hypercalcemia. /Vitamin D analogs/

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3541

    Decreased renal function without hypercalcemia has also been reported in patients with hypoparathyroidism after long-term vitamin D analog therapy. Before therapy with vitamin D analogs is initiated, serum phosphate concentrations must be controlled. To avoid ectopic calcification, the serum calcium (in mg/dL) times phosphorus (in mg/dL) should not be allowed to exceed 70. Because administration of vitamin D analogs may increase phosphate absorption, patients with renal failure may require adjustment in the dosage of aluminum-containing antacids used to decrease phosphate absorption. /Vitamin D analogs/

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3541

    For more Drug Warnings (Complete) data for CHOLECALCIFEROL (10 total), please visit the HSDB record page.

    4.4 Drug Indication

    Cholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets (or vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia. Concurrently, as one of the most commonly utilized forms of vitamin D, cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin D deficiency, as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease, among others.

    Treatment of osteoporosis

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    The in vivo synthesis of the predominant two biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of vitamin D3 cholecalciferol (or D2) occurs in the liver to yield 25-hydroxyvitamin D while the second hydroxylation happens in the kidneys to give 1, 25-dihydroxyvitamin D. These vitamin D metabolites subsequently facilitate the active absorption of calcium and phosphorus in the small intestine, serving to increase serum calcium and phosphate levels sufficiently to allow bone mineralization. Conversely, these vitamin D metabolites also assist in mobilizing calcium and phosphate from bone and likely increase the reabsorption of calcium and perhaps also of phosphate via the renal tubules. There exists a period of 10 to 24 hours between the administration of cholecalciferol and the initiation of its action in the body due to the necessity of synthesis of the active vitamin D metabolites in the liver and kidneys. It is parathyroid hormone that is responsible for the regulation of such metabolism at the level of the kidneys.

    5.2 MeSH Pharmacological Classification

    Bone Density Conservation Agents

    Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)

    Calcium-Regulating Hormones and Agents

    Hormones and molecules with calcium-regulating hormone-like actions that modulate OSTEOLYSIS and other extra-skeletal activities to maintain calcium homeostasis. (See all compounds classified as Calcium-Regulating Hormones and Agents.)

    Vitamins

    Organic substances that are required in small amounts for maintenance and growth, but which cannot be manufactured by the human body. (See all compounds classified as Vitamins.)

    5.3 ATC Code

    A - Alimentary tract and metabolism

    A11 - Vitamins

    A11C - Vitamin a and d, incl. combinations of the two

    A11CC - Vitamin d and analogues

    A11CC05 - Colecalciferol

    5.4 Absorption, Distribution and Excretion

    Absorption

    Cholecalciferol is readily absorbed from the small intestine if fat absorption is normal. Moreover, bile is necessary for absorption as well. In particular, recent studies have determined aspects about the absorption of vitamin D, like the fact that a) the 25-hydroxyvitamin D metabolite of cholecalciferol is absorbed to a greater extent than the nonhydroxy form of cholecalciferol, b) the quantity of fat with which cholecalciferol is ingested does not appear to largely affect its bioavailability, and c) age does not apparently effect vitamin D cholecalciferol.

    Route of Elimination

    It has been observed that administered cholecalciferol and its metabolites are excreted primarily in the bile and feces.

    Volume of Distribution

    Studies have determined that the mean central volume of distribution of administered cholecalciferol supplementation in a group of 49 kidney transplant patients was approximately 237 L.

    Clearance

    Studies have determined that the mean clearance value of administered cholecalciferol supplementation in a group of 49 kidney transplant patients was approximately 2.5 L/day.

    Readily absorbed from small intestine (proximal or distal); cholecalciferol may be absorbed more rapidly and completely than ergocalciferol.

    Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 2967

    Elimination: Biliary/renal. /Vitamin D and analogs/

    Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 2967

    Many vitamin D analogs are readily absorbed from the GI tract following oral administration if fat absorption is normal. The presence of bile is required for absorption of ergocalciferol and the extent of GI absorption may be decreased in patients with hepatic, biliary, or GI disease (e.g., Crohn's disease, Whipple's disease, sprue). Because vitamin D is fat soluble, it is incorporated into chylomicrons and absorbed via the lymphatic system; approximately 80% of ingested vitamin D appears to be absorbed systemically through this mechanism, principally in the small intestine. Although some evidence suggested that intestinal absorption of vitamin D may be decreased in geriatric adults, other evidence did not show clinically important age-related alterations in GI absorption of the vitamin in therapeutic doses. It currently is not known whether aging alters the GI absorption of physiologic amounts of vitamin D. /Vitamin D analogs/

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3543

    After absorption, ergocalciferol and cholecalciferol enter the blood via chylomicrons of lymph and then associate mainly with a specific alpha-globulin (vitamin D-binding protein). The hydroxylated metabolites of ergocalciferol and cholecalciferol also circulate associated with the same alpha-globulin. 25-Hydroxylated ergocalciferol and cholecalciferol are stored in fat and muscles for prolonged periods. Once vitamin D enters systemic circulation from lymph via the thoracic duct or from skin, it accumulates in the liver within a few hours.

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3543

    For more Absorption, Distribution and Excretion (Complete) data for CHOLECALCIFEROL (7 total), please visit the HSDB record page.

    5.5 Metabolism/Metabolites

    Within the liver, cholecalciferol is hydroxylated to calcifediol (25-hydroxycholecalciferol) by the enzyme vitamin D-25-hydroxylase. At the kidney, calcifediol subsequently serves as a substrate for 1-alpha-hydroxylase, yielding calcitriol (1,25-dihydroxycholecalciferol), the biologically active form of vitamin D3.

    Metabolic activation of cholecalciferol and ergocalciferol occurs in 2 steps, the first in the liver and the second in the kidneys. Metabolic activation of calcifediol occurs in the kidneys; dihydrotachysterol, alfacalcidol and doxercalciferol are activated in the liver.

    Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2006., p. 2967

    Normal combined (ie, 25-hydroxyvitamin D) plasma concentrations of 25-hydroxycholecalciferol (calcifediol) and 25-hydroxyergocalciferol, which are the major circulating metabolites of cholecalciferol and ergocalciferol, have been reported to range from 8-80 ng/mL, depending on the assay used, and vary with exposure to UV light. A commonly reported range for the lower limit of normal is 8-15 ng/mL, depending on geographic location (eg, Southern California would be higher than Massachusetts).

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3542

    In the liver, ergocalciferol and cholecalciferol are converted in the mitochondria to their 25-hydroxy derivatives by the enzyme vitamin D 25-hydroxylase. Vitamin D 25-hydroxylase activity is regulated in the liver by concentrations of vitamin D and its metabolites; therefore, increases in the systemic circulation of the 25-hydroxy metabolites following exposure to sunlight or ingestion of vitamin D are relatively modest compared with cumulative production or intake of the vitamin. Serum concentrations of nonhydroxylated vitamin D are short-lived as a result of storage in fat or metabolism in the liver. In the kidneys, these metabolites are further hydroxylated at the 1 position by the enzyme vitamin D 1-hydroxylase to their active forms, 1,25-dihydroxycholecalciferol (calcitriol) and 1,25-dihydroxyergocalciferol. ... Activity of the vitamin D 1-hydroxylase enzyme requires molecular oxygen, magnesium ion, and malate and is regulated principally by PTH in response to serum concentrations of calcium and phosphate, and perhaps by circulating concentrations of 1,25-dihydroxyergocalciferol and 1,25-dihydroxycholecalciferol. Other hormones (ie, cortisol, estrogens, prolactin, and growth hormone) also may influence the metabolism of cholecalciferol and ergocalciferol.

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3543

    The hepatic enzyme system responsible for 25-hydroxylation of vitamin D /(vitamin D-25 hydroxylase)/ is associated with the microsomal and mitochondrial fractions of homogenates and requires NADPH (nicotinamide adenine dinucleotide phosphate, reduced form) and molecular oxygen. ... The enzyme system /in kidney/ responsible for 1-hydroxylation of 25-OHD (25-hydroxycholecalciferol) /(25-OHD-1-alpha-hydroxylase)/ is associated with mitochondria in the proximal tubules. It is a mixed function oxidase and requires molecular oxygen and NADPH as cofactors. Cytochrome P450, a flavoprotein, and ferredoxin are components of the enzyme complex.

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1727

    5.6 Biological Half-Life

    At this time, there have been resources that document the half-life of cholecalciferol as being about 50 days while other sources have noted that the half-life of calcitriol (1,25-dihydroxyvitamin D3) is approximately 15 hours while that of calcidiol (25-hydroxyvitamin D3) is about 15 days. Moreover, it appears that the half-lives of any particular administration of vitamin d can vary due to variations in vitamin d binding protein concentrations and genotype in particular individuals.

    The Vitamin /D/ disappears from plasma with a half-life of 19 to 25 hr but is stored in fat depots for prolonged periods. ... The 25-hydroxy derivative has a biological half-life of 19 days ... The plasma half-life of calcitriol /(1,25-dihydroxy-vitamin D)/ is estimated to be between 3 and 5 days in human beings ...

    Hardman, J.G., L.E. Limbird, P.B., A.G. Gilman. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001., p. 1730

    5.7 Mechanism of Action

    Most individuals naturally generate adequate amounts of vitamin D through ordinary dietary intake of vitamin D (in some foods like eggs, fish, and cheese) and natural photochemical conversion of the vitamin D3 precursor 7-dehydrocholesterol in the skin via exposure to sunlight. Conversely, vitamin D deficiency can often occur from a combination of insufficient exposure to sunlight, inadequate dietary intake of vitamin D, genetic defects with endogenous vitamin D receptor, or even severe liver or kidney disease. Such deficiency is known for resulting in conditions like rickets or osteomalacia, all of which reflect inadequate mineralization of bone, enhanced compensatory skeletal demineralization, resultant decreased calcium ion blood concentrations, and increases in the production and secretion of parathyroid hormone. Increases in parathyroid hormone stimulate the mobilization of skeletal calcium and the renal excretion of phosphorus. This enhanced mobilization of skeletal calcium leads towards porotic bone conditions. Ordinarily, while vitamin D3 is made naturally via photochemical processes in the skin, both itself and vitamin D2 can be found in various food and pharmaceutical sources as dietary supplements. The principal biological function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet. At the liver, vitamin D3 or D2 is hydroxylated to 25-hydroxyvitamin D and then finally to the primary active metabolite 1,25-dihydroxyvitamin D in the kidney via further hydroxylation. This final metabolite binds to endogenous vitamin d receptors, which results in a variety of regulatory roles - including maintaining calcium balance, the regulation of parathyroid hormone, the promotion of the renal reabsorption of calcium, increased intestinal absorption of calcium and phosphorus, and increased calcium and phosphorus mobilization of calcium and phosphorus from bone to plasma to maintain balanced levels of each in bone and the plasma. In particular, calcitriol interacts with vitamin D receptors in the small intestine to enhance the efficiency of intestinal calcium and phosphorous absorption from about 10-15% to 30-40% and 60% increased to 80%, respectively. Furthermore, calcitriol binds with vitamin D receptors in osteoblasts to stimulate a receptor activator of nuclear factor kB ligand (or RANKL) which subsequently interacts with receptor activator of nuclear factor kB (NFkB) on immature preosteoclasts, causing them to become mature bone-resorbing osteoclasts. Such mature osteoclasts ultimately function in removing calcium and phosphorus from bone to maintain blood calcium and phosphorus levels. Moreover, calcitriol also stimulates calcium reabsorption from the glomerular filtrate in the kidneys. Additionally, it is believed that when calcitriol binds with nuclear vitamin D receptors, that this bound complex itself binds to retinoic acid X receptor (RXR) to generate a heterodimeric complex that consequently binds to specific nucleotide sequences in the DNA called vitamin D response elements. When bound, various transcription factors attach to this complex, resulting in either up or down-regulation of the associated gene's activity. It is thought that there may be as much as 200 to 2000 genes that possess vitamin D response elements or that are influenced indirectly to control a multitude of genes across the genome. It is in this way that cholecalciferol is believed to function in regulating gene transcription associated with cancer risk, autoimmune disorders, and cardiovascular disease linked to vitamin D deficiency. In fact, there has been some research to suggest calcitriol may also be able to prevent malignancies by inducing cellular maturation and inducing apoptosis and inhibiting angiogenesis, exhibit anti-inflammatory effects by inhibiting foam cell formation and promoting angiogenesis in endothelial colony-forming cells in vitro, inhibit immune reactions by enhancing the transcription of endogenous antibiotics like cathelicidin and regulate the activity and differentiation of CD4+ T cells, amongst a variety of other proposed actions.

    The principal biologic function of vitamin D is to maintain serum calcium and phosphorus concentrations within the normal range by enhancing the efficiency of the small intestine to absorb these minerals from the diet. Calcitriol (activated vitamin D) enhances the efficiency of intestinal calcium absorption along the entire small intestine, but principally in the duodenum and jejunum. Calcitriol also enhances phosphorus absorption along the entire small intestine, but principally in the jejunum and ileum. The activated forms of ergocalciferol, doxercalciferol, and cholecalciferol may have a negative feedback effect on parathyroid hormone (PTH) production.

    McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2005. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2005 (Plus Supplements)., p. 3542

    The most two important mechanisms by which vitamin D acts to maintain normal concentration of calcium and phosphate in plasma are to facilitate their absorption by the small intestine and to enhance their mobilization from bone. /Vitamin D/

    Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1541

    CEP/COS

    read-more
    read-moreread-more

    DISHMAN NETHERLANDS B.V. Veenendaal...

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Netherlands
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Cholecalciferol concentrate (oily form), 2 000 000 IU/g...

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 2007-347 - Rev 00
    Valid
    Chemical and TSE
    2014-07-18
    575
    blank

    01

    DISHMAN NETHERLANDS B.V. Veenendaal...

    Netherlands
    Pharmacy Expo
    Not Confirmed
    arrow

    DISHMAN NETHERLANDS B.V. Veenendaal...

    Netherlands
    arrow
    Pharmacy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Netherlands
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Cholecalciferol Concentrate (oily Form), 2 000 0...

    Certificate Number : R1-CEP 2007-347 - Rev 00

    Status : Valid

    Issue Date : 2014-07-18

    Type : Chemical and TSE

    Substance Number : 575

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    DISHMAN NETHERLANDS B.V. Veenendaal...

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Netherlands
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Cholecalciferol

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 2005-098 - Rev 03
    Withdrawn by Holder
    Chemical and TSE
    2012-02-07
    2023-07-20
    72
    blank

    02

    DISHMAN NETHERLANDS B.V. Veenendaal...

    Netherlands
    Pharmacy Expo
    Not Confirmed
    arrow

    DISHMAN NETHERLANDS B.V. Veenendaal...

    Netherlands
    arrow
    Pharmacy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Netherlands
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Cholecalciferol

    Certificate Number : R1-CEP 2005-098 - Rev 03

    Status : Withdrawn by Holder

    Issue Date : 2012-02-07

    Type : Chemical and TSE

    Substance Number : 72

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    FERMENTA BIOTECH LIMITED Thane (W) ...

    Contact Supplier
    • FDA
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Cholecalciferol

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 2007-292 - Rev 03
    Valid
    Chemical and TSE
    2023-01-24
    72
    blank

    03

    FERMENTA BIOTECH LIMITED Thane (W) ...

    India
    Pharmacy Expo
    Not Confirmed
    arrow

    FERMENTA BIOTECH LIMITED Thane (W) ...

    India
    arrow
    Pharmacy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Cholecalciferol

    Certificate Number : R1-CEP 2007-292 - Rev 03

    Status : Valid

    Issue Date : 2023-01-24

    Type : Chemical and TSE

    Substance Number : 72

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    FERMENTA BIOTECH LIMITED Thane (W) ...

    Contact Supplier
    • FDA
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Cholecalciferol concentrate (oily form), 1 000 000 IU/g...

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R0-CEP 2021-089 - Rev 00
    Valid
    Chemical and TSE
    2022-07-29
    575
    blank

    04

    FERMENTA BIOTECH LIMITED Thane (W) ...

    India
    Pharmacy Expo
    Not Confirmed
    arrow

    FERMENTA BIOTECH LIMITED Thane (W) ...

    Contact Supplier
    • FDA
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Cholecalciferol

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 2016-266 - Rev 00
    Valid
    Chemical and TSE
    2021-12-21
    72
    blank

    05

    FERMENTA BIOTECH LIMITED Thane (W) ...

    India
    Pharmacy Expo
    Not Confirmed
    arrow

    FERMENTA BIOTECH LIMITED Thane (W) ...

    India
    arrow
    Pharmacy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Cholecalciferol

    Certificate Number : R1-CEP 2016-266 - Rev 00

    Status : Valid

    Issue Date : 2021-12-21

    Type : Chemical and TSE

    Substance Number : 72

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    POLYMED THERAPEUTICS, INC. Houston ...

    Contact Supplier
      • fda
      • EDQM
      • WHO-GMP
      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
      Post an Enquiry Post an Enquiry
      Flag U.S.A
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Cholecalciferol

      Portfolio PDF

      Product Web Link

      Virtual Booth

      Digital Content

      Website

      Corporate PDF

      R0-CEP 2013-282 - Rev 00
      Withdrawn by Holder
      Chemical and TSE
      2015-09-10
      2019-03-20
      72
      blank

      06

      POLYMED THERAPEUTICS, INC. Houston ...

      U.S.A
      Pharmacy Expo
      Not Confirmed
      arrow

      POLYMED THERAPEUTICS, INC. Houston ...

      U.S.A
      arrow
      Pharmacy Expo
      Not Confirmed
      • fda
      • EDQM
      • WHO-GMP
      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
      Post an Enquiry Post an Enquiry
      Flag U.S.A
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Cholecalciferol

      Certificate Number : R0-CEP 2013-282 - Rev 00

      Status : Withdrawn by Holder

      Issue Date : 2015-09-10

      Type : Chemical and TSE

      Substance Number : 72

      blank

      Portfolio PDF

      Product Web Link

      Virtual Booth

      Digital Content

      Website

      Corporate PDF

      DSM Nutritional Products Ltd. Kaise...

      Contact Supplier
      • FDA
      • EDQM
      • fda
      • EDQM
      • WHO-GMP
      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
      Post an Enquiry Post an Enquiry
      Flag Netherlands
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Cholecalciferol concentrate (oily form), 1 000 000 IU/g...

      Portfolio PDF

      Product Web Link

      Virtual Booth

      Digital Content

      Website

      Corporate PDF

      R0-CEP 2021-055 - Rev 00
      Valid
      Chemical and TSE
      2022-11-16
      575
      blank

      07

      DSM Nutritional Products Ltd. Kaise...

      Netherlands
      Pharmacy Expo
      Not Confirmed
      arrow

      DSM Nutritional Products Ltd. Kaise...

      Contact Supplier
      • FDA
      • EDQM
      • fda
      • EDQM
      • WHO-GMP
      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
      Post an Enquiry Post an Enquiry
      Flag Netherlands
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Cholecalciferol concentrate (powder form), 100 000 IU/g...

      Portfolio PDF

      Product Web Link

      Virtual Booth

      Digital Content

      Website

      Corporate PDF

      R1-CEP 2015-199 - Rev 00
      Valid
      Chemical and TSE
      2021-09-03
      574
      blank

      08

      DSM Nutritional Products Ltd. Kaise...

      Netherlands
      Pharmacy Expo
      Not Confirmed
      arrow

      DSM Nutritional Products Ltd. Kaise...

      Contact Supplier
      • FDA
      • EDQM
      • fda
      • EDQM
      • WHO-GMP
      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
      Post an Enquiry Post an Enquiry
      Flag Netherlands
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Cholecalciferol concentrate (powder form), 100 000 IU/g...

      Portfolio PDF

      Product Web Link

      Virtual Booth

      Digital Content

      Website

      Corporate PDF

      R0-CEP 2019-003 - Rev 00
      Valid
      Chemical and TSE
      2020-11-23
      574
      blank

      09

      DSM Nutritional Products Ltd. Kaise...

      Netherlands
      Pharmacy Expo
      Not Confirmed
      arrow

      DSM Nutritional Products Ltd. Kaise...

      Contact Supplier
      • FDA
      • EDQM
      • fda
      • EDQM
      • WHO-GMP
      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
      Post an Enquiry Post an Enquiry
      Flag Netherlands
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Cholecalciferol

      Portfolio PDF

      Product Web Link

      Virtual Booth

      Digital Content

      Website

      Corporate PDF

      R1-CEP 2003-036 - Rev 01
      Withdrawn by Holder
      Chemical and TSE
      2008-12-19
      2024-03-21
      72
      blank

      10

      DSM Nutritional Products Ltd. Kaise...

      Netherlands
      GRx+Biosims
      Not Confirmed
      arrow

      DSM Nutritional Products Ltd. Kaise...

      Netherlands
      arrow
      GRx+Biosims
      Not Confirmed
      • fda
      • EDQM
      • WHO-GMP
      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
      Post an Enquiry Post an Enquiry
      Flag Netherlands
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Cholecalciferol

      Certificate Number : R1-CEP 2003-036 - Rev 01

      Status : Withdrawn by Holder

      Issue Date : 2008-12-19

      Type : Chemical and TSE

      Substance Number : 72

      blank

      Portfolio PDF

      Product Web Link

      Virtual Booth

      Digital Content

      Website

      Corporate PDF

      Only 10 entries up to this point, click to access all click full view read-more
      click full view
      Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

      DRUG PRODUCT COMPOSITIONS

      Do you need Business Intel? Ask us

      DOSAGE - SOLUTION;INTRAVENOUS - 2 IU/ML;40MG/...DOSAGE - SOLUTION;INTRAVENOUS - 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML

      USFDA APPLICATION NUMBER - 21163

      read-more

      DOSAGE - SOLUTION;INTRAVENOUS - 2 IU/ML;40MG/...DOSAGE - SOLUTION;INTRAVENOUS - 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML

      USFDA APPLICATION NUMBER - 21163

      read-more

      DOSAGE - TABLET;ORAL - EQ 70MG BASE;2,800 IU

      USFDA APPLICATION NUMBER - 21762

      read-more

      DOSAGE - TABLET;ORAL - EQ 70MG BASE;5,600 IU

      USFDA APPLICATION NUMBER - 21762

      read-more

      Related Excipient Companies

      Upload your portfolio for free, ask us

      Excipients by Applications

      Click here to find the perfect excipient manufacturers by their capabilities

      Fillers, Diluents & Binders

      read-more
      read-more

      Coating Systems & Additives

      read-more
      read-more

      Thickeners and Stabilizers

      read-more
      read-more

      Taste Masking

      read-more
      read-more

      Solubilizers

      read-more
      read-more

      Direct Compression

      read-more
      read-more

      Controlled & Modified Release

      read-more
      read-more

      Granulation

      read-more
      read-more

      Topical

      read-more
      read-more

      Parenteral

      read-more
      read-more

      Film Formers & Plasticizers

      read-more
      read-more

      Disintegrants & Superdisintegrants

      read-more
      read-more

      Chewable & Orodispersible Aids

      read-more
      read-more

      Lubricants & Glidants

      read-more
      read-more

      Co-Processed Excipients

      read-more
      read-more

      Rheology Modifiers

      read-more
      read-more

      Emulsifying Agents

      read-more
      read-more

      Empty Capsules

      read-more
      read-more

      API Stability Enhancers

      read-more
      read-more

      Surfactant & Foaming Agents

      read-more
      read-more

      Coloring Agents

      read-more
      read-more

      Vegetarian Capsules

      read-more
      read-more

      Soft Gelatin

      read-more
      read-more

      Digital Content read-more

      Create Content with PharmaCompass, ask us

      DATA COMPILATION #PharmaFlow

      read-more
      read-more

      NEWS #PharmaBuzz

      read-more
      read-more

      Global Sales Information

      Do you need Business Intel? Ask us

      Market Place

      Do you need sourcing support? Ask us

      REF. STANDARDS & IMPURITIES

      Upload your portfolio for free, ask us

      USP

      read-more
      read-more

      ANALYTICAL

      Upload your methods for free, ask us

      Analytical Methods

      read-more
      read-more

      ABOUT THIS PAGE

      Looking for 67-97-0 / Vitamin D3 API manufacturers, exporters & distributors?

      Vitamin D3 manufacturers, exporters & distributors 1

      59

      PharmaCompass offers a list of Vitamin D3 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vitamin D3 manufacturer or Vitamin D3 supplier for your needs.

      Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vitamin D3 manufacturer or Vitamin D3 supplier.

      PharmaCompass also assists you with knowing the Vitamin D3 API Price utilized in the formulation of products. Vitamin D3 API Price is not always fixed or binding as the Vitamin D3 Price is obtained through a variety of data sources. The Vitamin D3 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

      API | Excipient name

      Vitamin D3

      Synonyms

      67-97-0, Colecalciferol, Calciol, Oleovitamin d3, Ricketon, Arachitol

      Cas Number

      67-97-0

      About Vitamin D3

      Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.

      Vi-de-3-hydrosol Manufacturers

      A Vi-de-3-hydrosol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vi-de-3-hydrosol, including repackagers and relabelers. The FDA regulates Vi-de-3-hydrosol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vi-de-3-hydrosol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

      click here to find a list of Vi-de-3-hydrosol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

      Vi-de-3-hydrosol Suppliers

      A Vi-de-3-hydrosol supplier is an individual or a company that provides Vi-de-3-hydrosol active pharmaceutical ingredient (API) or Vi-de-3-hydrosol finished formulations upon request. The Vi-de-3-hydrosol suppliers may include Vi-de-3-hydrosol API manufacturers, exporters, distributors and traders.

      click here to find a list of Vi-de-3-hydrosol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

      Vi-de-3-hydrosol USDMF

      A Vi-de-3-hydrosol DMF (Drug Master File) is a document detailing the whole manufacturing process of Vi-de-3-hydrosol active pharmaceutical ingredient (API) in detail. Different forms of Vi-de-3-hydrosol DMFs exist exist since differing nations have different regulations, such as Vi-de-3-hydrosol USDMF, ASMF (EDMF), JDMF, CDMF, etc.

      A Vi-de-3-hydrosol DMF submitted to regulatory agencies in the US is known as a USDMF. Vi-de-3-hydrosol USDMF includes data on Vi-de-3-hydrosol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vi-de-3-hydrosol USDMF is kept confidential to protect the manufacturer’s intellectual property.

      click here to find a list of Vi-de-3-hydrosol suppliers with USDMF on PharmaCompass.

      Vi-de-3-hydrosol JDMF

      The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

      The Vi-de-3-hydrosol Drug Master File in Japan (Vi-de-3-hydrosol JDMF) empowers Vi-de-3-hydrosol API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

      PMDA reviews the Vi-de-3-hydrosol JDMF during the approval evaluation for pharmaceutical products. At the time of Vi-de-3-hydrosol JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

      click here to find a list of Vi-de-3-hydrosol suppliers with JDMF on PharmaCompass.

      Vi-de-3-hydrosol CEP

      A Vi-de-3-hydrosol CEP of the European Pharmacopoeia monograph is often referred to as a Vi-de-3-hydrosol Certificate of Suitability (COS). The purpose of a Vi-de-3-hydrosol CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Vi-de-3-hydrosol EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Vi-de-3-hydrosol to their clients by showing that a Vi-de-3-hydrosol CEP has been issued for it. The manufacturer submits a Vi-de-3-hydrosol CEP (COS) as part of the market authorization procedure, and it takes on the role of a Vi-de-3-hydrosol CEP holder for the record. Additionally, the data presented in the Vi-de-3-hydrosol CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Vi-de-3-hydrosol DMF.

      A Vi-de-3-hydrosol CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Vi-de-3-hydrosol CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

      click here to find a list of Vi-de-3-hydrosol suppliers with CEP (COS) on PharmaCompass.

      Vi-de-3-hydrosol WC

      A Vi-de-3-hydrosol written confirmation (Vi-de-3-hydrosol WC) is an official document issued by a regulatory agency to a Vi-de-3-hydrosol manufacturer, verifying that the manufacturing facility of a Vi-de-3-hydrosol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Vi-de-3-hydrosol APIs or Vi-de-3-hydrosol finished pharmaceutical products to another nation, regulatory agencies frequently require a Vi-de-3-hydrosol WC (written confirmation) as part of the regulatory process.

      click here to find a list of Vi-de-3-hydrosol suppliers with Written Confirmation (WC) on PharmaCompass.

      Vi-de-3-hydrosol NDC

      National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vi-de-3-hydrosol as an active pharmaceutical ingredient (API).

      Finished drug products

      The FDA updates the NDC directory daily. The NDC numbers for Vi-de-3-hydrosol API and other APIs are published in this directory by the FDA.

      Unfinished drugs

      The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

      Pharmaceutical companies that manufacture Vi-de-3-hydrosol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

      Compounded drug products

      The NDC directory also contains data on finished compounded human drug products that contain Vi-de-3-hydrosol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vi-de-3-hydrosol NDC to their finished compounded human drug products, they may choose to do so.

      click here to find a list of Vi-de-3-hydrosol suppliers with NDC on PharmaCompass.

      Vi-de-3-hydrosol GMP

      Vi-de-3-hydrosol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

      GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

      PharmaCompass offers a list of Vi-de-3-hydrosol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vi-de-3-hydrosol GMP manufacturer or Vi-de-3-hydrosol GMP API supplier for your needs.

      Vi-de-3-hydrosol CoA

      A Vi-de-3-hydrosol CoA (Certificate of Analysis) is a formal document that attests to Vi-de-3-hydrosol's compliance with Vi-de-3-hydrosol specifications and serves as a tool for batch-level quality control.

      Vi-de-3-hydrosol CoA mostly includes findings from lab analyses of a specific batch. For each Vi-de-3-hydrosol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

      Vi-de-3-hydrosol may be tested according to a variety of international standards, such as European Pharmacopoeia (Vi-de-3-hydrosol EP), Vi-de-3-hydrosol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vi-de-3-hydrosol USP).

      Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
      For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
      Ask Us for Pharmaceutical Supplier and Partner
      Ask Us, Find A Supplier / Partner
      No Commissions, No Strings Attached, Get Connected for FREE

      What are you looking for?

      How can we help you?

      The request can't be empty

      Please read our Privacy Policy carefully

      You must agree to the privacy policy

      The name can't be empty
      The company can't be empty.
      The email can't be empty Please enter a valid email.
      The mobile can't be empty

      Market Place

      Market Place

      PharmaCompass

      Home

      Market Place

      Menu

      Post Enquiry

      Post Enquiry

      Market Place

      Market Place

      Search